What changed in this filing

/stocks — the workspaceLOADING

Item 2. Management’s Discussion and Analysis

2025-11-04 compared with 2025-08-05 · 97 added, 94 removed, 75 unchanged (72% of the section changed)

1 unchanged sentence

Our discussions below in this Item 2 are based upon the more detailed discussions about our business, operations and financial condition included in our Annual Report on Form 10-K for the fiscal year ended December 29, 2024, under Part II, Item 7 of that Form 10-K.

Our discussions here focus on our results during the quarter and six months ended June 29, 2025, or as of, June 29, 2025, and the comparable periods of 2024, and to the extent applicable, any material changes from the information discussed in that Form 10-K or other important intervening developments or information since that time.

Our discussions here focus on our results during the quarter and nine months ended September 28, 2025, or as of, September 28, 2025, and the comparable periods of 2024, and to the extent applicable, any material changes from the information discussed in that Form 10-K or other important intervening developments or information since that time.

These discussions should be read in conjunction with that Form 10-K for more detailed and background information.

The six-month periods ended June 29, 2025 and June 30, 2024 both include 26 weeks.

The three-month periods ended June 29, 2025 and June 30, 2024 both include 13 weeks.

The nine-month periods ended September 28, 2025 and September 29, 2024 both include 39 weeks.

The three-month periods ended September 28, 2025 and September 29, 2024 both include 13 weeks.

Forward-Looking Statements

3 unchanged sentences

Executive Overview

During the quarter ended June 29, 2025, we had consolidated net sales of $375.5 million, up 8.3% compared to $346.6 million in the second quarter last year, primarily due to higher customer demand — particularly in the education, healthcare, and corporate office market segments — and higher average sales prices.

Consolidated operating income was $52.0 million for the second quarter of 2025 compared to $38.2 million in the second quarter last year, primarily due to higher sales, higher gross profit margin driven by lower manufacturing costs due to favorable fixed cost absorption on higher volume and production efficiencies, and favorable product mix.

Consolidated net income for the quarter ended June 29, 2025, was $32.6 million or $0.55 per diluted share, compared to $22.6 million or $0.38 per diluted share in the second quarter last year.

During the first six months of 2025, we had consolidated net sales of $672.9 million, up 5.7% compared to $636.4 million in the first six months of last year, primarily due to higher customer demand — particularly in the education and healthcare market segments.

Consolidated operating income was $75.3 million for the first six months of 2025, compared to $62.6 million in the same period last year, primarily due to higher sales and higher gross profit margin as discussed above.

Consolidated net income for the six months ended June 29, 2025, was $45.6 million or $0.77 per diluted share, compared to $36.7 million or $0.63 per diluted share in the same period last year.

During the quarter ended September 28, 2025, we had consolidated net sales of $364.5 million, up 5.9% compared to $344.3 million in the third quarter last year, primarily due to higher customer demand — particularly in the healthcare and corporate office market segments — and higher average sales prices.

Consolidated operating income was $53.4 million for the third quarter of 2025 compared to $42.2 million in the third quarter last year, primarily due to higher sales and higher gross profit margin driven by higher pricing and favorable product mix combined with manufacturing efficiencies that offset higher raw material and tariff-related costs.

Consolidated net income for the quarter ended September 28, 2025, was $46.1 million, or $0.78 per diluted share, compared to $28.4 million, or $0.48 per diluted share, in the third quarter last year.

During the first nine months of 2025, we had consolidated net sales of $1,037.5 million, up 5.8% compared to $980.6 million in the first nine months of last year, primarily due to higher customer demand — particularly in the healthcare and education market segments.

Consolidated operating income was $128.6 million for the first nine months of 2025, compared to $104.8 million in the same period last year, primarily due to higher sales and higher gross profit margin due to the same factors discussed above for the third quarter 2025.

Consolidated net income for the nine months ended September 28, 2025, was $91.7 million, or $1.55 per diluted share, compared to $65.2 million, or $1.11 per diluted share, in the same period last year.

Impact of Macroeconomic Trends

Disruptions in global economic markets due to the potential impact of government-imposed tariffs and retaliatory tariffs, fluctuating freight costs, supply chain challenges and disruptions, significant pressures in the commercial office market globally, inflation, slow market conditions in certain parts of the globe, the Russia-Ukraine war and the conflict in the Middle East, all pose challenges which may adversely affect our future performance.

Disruptions in global economic markets due to the impact of government-imposed tariffs and retaliatory tariffs, supply chain challenges and disruptions, significant pressures in the commercial office market globally, inflation, slow market conditions in certain parts of the globe, the Russia-Ukraine war and the conflict in the Middle East, all pose challenges which may adversely affect our future performance.

W e plan to continue evaluating our cost structure and global manufacturing footprint to identify and activate opportunities to decrease costs and optimize our global cost structure.

1 unchanged sentence

Consolidated Results

The following table presents, as a percentage of net sales, certain items included in our consolidated condensed statements of operations for the three-month and six-month periods ended June 29, 2025 and June 30, 2024:

Three Months Ended Six Months Ended

June 29, 2025 June 30, 2024 June 29, 2025 June 30, 2024

The following table presents, as a percentage of net sales, certain items included in our consolidated condensed statements of operations for the three-month and nine-month periods ended September 28, 2025 and September 29, 2024:

Three Months Ended Nine Months Ended

September 28, 2025 September 29, 2024 September 28, 2025 September 29, 2024

Net sales 100.0 % 100.0 % 100.0 % 100.0 %

3 unchanged sentences

Operating income 14.6 12.3 12.4 10.7

Interest/Other expense (income), net 2.1 2.0 2.1 2.0

Interest/Other expense, net

1.3 1.8 1.9 1.9

Income before income tax expense 13.3 10.5 10.5 8.8

2 unchanged sentences

Consolidated Net Sales

Below is information regarding our consolidated net sales, and analysis of those results, for the three-month and six-month periods ended June 29, 2025, and June 30, 2024:

Below is information regarding our consolidated net sales, and analysis of those results, for the three-month and nine-month periods ended September 28, 2025, and September 29, 2024:

Three Months Ended Percentage

Change Six Months Ended Percentage

June 29, 2025 June 30, 2024 June 29, 2025 June 30, 2024

Change Nine Months Ended Percentage

September 28, 2025 September 29, 2024 September 28, 2025 September 29, 2024

(in thousands) (in thousands)

Consolidated net sales $ 364,526 $ 344,270 5.9 % $ 1,037,461 $ 980,648 5.8 %

For the quarter ended June 29, 2025, consolidated net sales increased $28.9 million (8.3%) versus the comparable period in 2024, primarily due to higher sales volume (approximately 6%) and higher average sales prices (approximately 2%).

Currency fluctuations had a positive impact on consolidated net sales of approximately $4.4 million (1.3%) for the second quarter of 2025, compared to the same period last year from the strengthening of the Euro against the U.S.

On a market segment basis, the sales increase was primarily in the education, healthcare, and corporate office market segments.

For the six months ended June 29, 2025, consolidated net sales increased $36.6 million (5.7%) versus the comparable period in 2024, primarily due to higher sales volume (approximately 5%) and higher average sales prices (approximately 1%).

Currency fluctuations had no material impact on consolidated net sales for the first six months of 2025.

On a market segment basis, the sales increase was primarily in the education, healthcare, and retail market segments partially offset by a decrease in the corporate office market segment.

For the quarter ended September 28, 2025, consolidated net sales increased $20.3 million (5.9%) versus the comparable period in 2024, primarily due to higher average sales prices (approximately 4%) and higher sales volume (approximately 2%).

Currency fluctuations had a positive impact on consolidated net sales of approximately $5.9 million (1.7%) for the third quarter of 2025, compared to the same period last year, primarily from the strengthening of the Euro against the U.S.

On a market segment basis, the sales increase was primarily in the healthcare and corporate office market segments, partially offset by lower sales in the retail and education market segments.

For the nine months ended September 28, 2025, consolidated net sales increased $56.8 million (5.8%) versus the comparable period in 2024, primarily due to higher sales volume (approximately 4%) - particularly rubber sales -- and higher average sales prices (approximately 2%).

Currency fluctuations had a positive impact on consolidated net sales of approximately $6.0 million (0.6%) for the first nine months of 2025 due to the factors discussed above for the current quarter.

On a market segment basis, the sales increase was primarily in the healthcare, education, public buildings, and transportation market segments.

Consolidated Cost and Expenses

The following table presents our consolidated cost of sales and selling, general and administrative expenses for the three-month and six-month periods ended June 29, 2025, and June 30, 2024:

The following table presents our consolidated cost of sales and selling, general and administrative expenses for the three-month and nine-month periods ended September 28, 2025, and September 29, 2024:

Three Months Ended Percentage

Change Six Months Ended Percentage

June 29, 2025 June 30, 2024 June 29, 2025 June 30, 2024

Change Nine Months Ended Percentage

September 28, 2025 September 29, 2024 September 28, 2025 September 29, 2024

(in thousands) (in thousands)

2 unchanged sentences

Consolidated Cost of Sales

For the quarter ended June 29, 2025, consolidated cost of sales increased $3.5 million (1.6%) compared to the second quarter of 2024, primarily due to higher sales and higher input costs due to inflation mostly offset by lower manufacturing costs driven by favorable fixed cost absorption on higher volume and production efficiencies.

Currency translation had a negative impact on consolidated cost of sales in the second quarter of 2025 and partially increased our costs by approximately $3.0 million (1.3%) compared to the same period last year.

As a percentage of net sales, our cost of sales decreased to 60.6% for the second quarter of 2025 versus 64.6% for the second quarter of 2024.

For the six months ended June 29, 2025, consolidated cost of sales increased $10.6 million (2.6%) versus the comparable period in 2024, primarily due to higher sales partially offset by lower manufacturing costs as discussed above.

Currency translation had no material impact on consolidated cost of sales for the first six months of 2025 compared to the same period last year.

As a percentage of net sales, our cost of sales decreased to 61.5% for the first six months of 2025 versus 63.4% for the first six months of 2024.

For the quarter ended September 28, 2025, consolidated cost of sales increased $4.2 million (2.0%) compared to the third quarter of 2024, primarily due to higher sales volume and tariff costs on rubber and luxury vinyl tile products imported into the U.S.

(approximately $2.8 million) partially offset by lower manufacturing costs driven by favorable fixed cost absorption and production efficiencies.

Currency translation had a negative impact on consolidated cost of sales in the third quarter of 2025 and increased our costs by approximately $3.5 million (1.6%) compared to the same period last year.

As a percentage of net sales, our cost of sales decreased to 60.6% for the third quarter of 2025 versus 62.9% for the third quarter of 2024.

For the nine months ended September 28, 2025, consolidated cost of sales increased $14.9 million (2.4%) versus the comparable period in 2024, primarily due to higher sales and tariff costs as discussed above partially offset by lower manufacturing costs driven by favorable fixed cost absorption and production efficiencies.

Currency translation had a negative impact on consolidated cost of sales for the first nine months of 2025 and increased our costs by approximately $3.5 million (0.6%) compared to the same period last year.

As a percentage of net sales, our cost of sales decreased to 61.2% for the first nine months of 2025 versus 63.2% for the first nine months of 2024.

Consolidated Gross Profit

For the quarter ended June 29, 2025, gross profit, as a percentage of net sales, was 39.4% compared with 35.4% in the same period last year.

The increase in gross profit percentage was primarily due to lower manufacturing costs per unit (approximately 4%) driven by favorable fixed cost absorption and production efficiencies.

For the six months ended June 29, 2025, gross profit, as a percentage of net sales, was 38.5% compared with 36.6% in the same period last year.

The increase in gross profit percentage was primarily due to lower manufacturing costs (approximately 2%) due to the factors discussed above.

For the quarter ended September 28, 2025, gross profit, as a percentage of net sales, was 39.4% compared with 37.1% in the same period last year.

The increase in gross profit percentage was primarily due to higher average sales prices and favorable product mix (approximately 1%) combined with favorable manufacturing costs (approximately 1%) as discussed above.

For the nine months ended September 28, 2025, gross profit, as a percentage of net sales, was 38.8% compared with 36.8% in the same period last year.

The increase in gross profit percentage was primarily due to higher average sales prices and favorable product mix (approximately 1%) and lower manufacturing costs (approximately 1%) as discussed above.

Consolidated Selling, General and Administrative (“SG&A”) Expenses

For the quarter ended June 29, 2025, consolidated SG&A expenses increased $11.5 million (13.6%) versus the comparable period in 2024.

Currency fluctuations had a negative impact on consolidated SG&A expenses of approximately $1.0 million (1.2%) in the second quarter of 2025 compared to the same period last year.

SG&A expenses were higher for the second quarter of 2025 primarily due to (i) higher employee benefits and labor costs of $5.0 million, (ii) higher variable compensation of $2.9 million as a result of higher commissions on higher sales and higher bonus costs driven by improved operating results, and (iii) higher severance costs of $2.7 million primarily due to a previously announced employee separation.

As a percentage of net sales, SG&A expenses increased to 25.5% for the second quarter of 2025 versus 24.4% for the second quarter of 2024.

For the six months ended June 29, 2025, consolidated SG&A expenses increased $13.2 million (7.8%) versus the comparable period in 2024.

Currency translation had no material impact on consolidated SG&A expenses in the first six months of 2025 compared to the same period last year.

SG&A expenses were higher for the first six months of 2025 primarily due to the factors discussed above for the second quarter of 2025.

As a percentage of net sales, SG&A expenses increased to 27.3% for the first six months of 2025 versus 26.8% for the first six months of 2024.

For the quarter ended September 28, 2025, consolidated SG&A expenses increased $4.8 million (5.6%) versus the comparable period in 2024.

Currency fluctuations had a negative impact on consolidated SG&A expenses of approximately $1.3 million (1.5%) in the third quarter of 2025 compared to the same period last year.

SG&A expenses were higher for the third quarter of 2025 primarily due to (i) higher variable compensation of $3.4 million as a result of higher commissions on higher sales and (ii) higher bonus costs driven by improved operating results and higher labor costs of approximately $1.3 million.

As a percentage of net sales, SG&A expenses were 24.8% for both the third quarter of 2025 and the third quarter of 2024.

For the nine months ended September 28, 2025, consolidated SG&A expenses increased $18.1 million (7.1%) versus the comparable period in 2024.

Currency translation had a negative impact on consolidated SG&A expenses of approximately $1.3 million (0.5%) in the first nine months of 2025 compared to the same period last year.

SG&A expenses were higher for the first nine months of 2025 primarily due to (i) higher variable compensation of $6.9 million as a result of higher commissions on higher sales and higher bonus costs driven by improved operating results, (ii) higher employee benefits and labor costs of $5.5 million, and (iii) higher severance costs of $3.5 million due to employee separations.

As a percentage of net sales, SG&A expenses increased to 26.4% for the first nine months of 2025 versus 26.1% for the first nine months of 2024.

Interest Expense

During the quarter ended June 29, 2025, interest expense was $4.4 million, a decrease of $1.7 million from the comparable period in 2024, primarily due to lower outstanding term loan borrowings under the Facility.

For the six months ended June 29, 2025, interest expense was $8.9 million, a decrease of $3.7 million from the comparable period in 2024, primarily due to lower outstanding term loan borrowings as discussed above.

During the quarter ended September 28, 2025, interest expense was $4.2 million, a decrease of $1.5 million from the comparable period in 2024, primarily due to lower outstanding term loan borrowings under the Facility.

For the nine months ended September 28, 2025, interest expense was $13.1 million, a decrease of $5.2 million from the comparable period in 2024, primarily due to lower outstanding term loan borrowings as discussed above.

Provision for Income Taxes

The effective tax rate for the three and six months ended June 29, 2025, was 26.3% and 25.7%, respectively, compared to 27.6% and 26.7% for the same periods in 2024.

The decrease in the effective tax rate for the three months ended June 29, 2025 as compared to the three months ended June 30, 2024 was primarily due to favorable changes in the geographic mix of earnings and favorable changes related to the cash surrender value of Company-owned life insurance.

The decrease in the effective tax rate for the six months ended June 29, 2025 as compared to the six months ended June 30, 2024 was primarily due to favorable changes in the geographic mix of earnings and an increase in tax benefits related to share-based compensation.

The effective tax rate for the three and nine months ended September 28, 2025, was 4.8% and 16.5%, respectively, compared to 21.2% and 24.4% for the same periods in 2024.

The decrease in the effective tax rate for the three and nine months ended September 28, 2025, compared to the same periods in the prior year was primarily due to the remeasurement and adjustment of deferred taxes and a favorable mix of geographic earnings.

See Note 12 entitled “Income Taxes” of Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information, including a discussion of the remeasurement and adjustment of deferred taxes that was recognized in the third quarter of 2025.

Segment Operating Results

AMS Segment – Net Sales and Adjusted Operating Income (“AOI”)

The following table presents AMS segment net sales and AOI for the three-month and six-month periods ended June 29, 2025, and June 30, 2024:

Three Months Ended Percentage Change Six Months Ended Percentage Change

June 29, 2025 June 30, 2024 June 29, 2025 June 30, 2024

The following table presents AMS segment net sales and AOI for the three-month and nine-month periods ended September 28, 2025, and September 29, 2024:

Three Months Ended Percentage Change Nine Months Ended Percentage Change

September 28, 2025 September 29, 2024 September 28, 2025 September 29, 2024

(in thousands) (in thousands)

5 unchanged sentences

See Note 10 entitled “Segment Information” of Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information.

During the second quarter of 2025, net sales in AMS increased 11.4% versus the comparable period in 2024, primarily due to higher sales volume and higher average sales prices.

On a market segment basis, the AMS sales increase was primarily in the education, healthcare, and corporate office market segments.

During the first six months of 2025, net sales in AMS increased 9.0% versus the comparable period in 2024, primarily due to higher sales volume and pricing as discussed above.

On a market segment basis, the AMS sales increase was primarily in education, healthcare, and retail market segments.

AOI in AMS increased 81.3% during the second quarter of 2025 compared to the prior year period, primarily due to higher sales and gross profit margin due to favorable product mix, production efficiencies, and favorable fixed cost absorption.

As a percentage of net sales, AOI increased to 20.4% during the second quarter of 2025 compared to 12.5% in the same period last year.

AOI in AMS increased 52.6% during the first six months of 2025 compared to the prior year period, primarily due to higher sales and gross profit margin as discussed above.

As a percentage of net sales, AOI increased to 16.4% during the first six months of 2025 compared to 11.7% in the same period last year.

During the third quarter of 2025, net sales in AMS increased 4.0% versus the comparable period in 2024, primarily due to higher average sales prices and higher volume.

On a market segment basis, the AMS sales increase was primarily in the healthcare and corporate office market segments partially offset by a decrease in the retail market segment.

During the first nine months of 2025, net sales in AMS increased 7.2% versus the comparable period in 2024, primarily due to higher average sales prices and higher sales volume - particularly increased rubber flooring volume.

On a market segment basis, the AMS sales increase was primarily in the healthcare, education, and corporate office market segments.

AOI in AMS increased 25.8% during the third quarter of 2025 compared to the prior year period, primarily due to higher sales and gross profit margin due to higher average sales prices, favorable product mix, and manufacturing efficiencies, partially offset by tariff costs.

As a percentage of net sales, AOI increased to 18.5% during the third quarter of 2025 compared to 15.3% in the same period last year.

AOI in AMS increased 41.4% during the first nine months of 2025 compared to the prior year period, primarily due to higher sales and gross profit margin due to higher average sales prices, favorable product mix, and manufacturing efficiencies, partially offset by tariff costs.

As a percentage of net sales, AOI increased to 17.1% during the first nine months of 2025 compared to 13.0% in the same period last year.

EAAA Segment – Net Sales and AOI

The following table presents EAAA segment net sales and AOI for the three-month and six-month periods ended June 29, 2025, and June 30, 2024:

Three Months Ended Percentage Change Six Months Ended Percentage Change

June 29, 2025 June 30, 2024 June 29, 2025 June 30, 2024

The following table presents EAAA segment net sales and AOI for the three-month and nine-month periods ended September 28, 2025, and September 29, 2024:

Three Months Ended Percentage Change Nine Months Ended Percentage Change

September 28, 2025 September 29, 2024 September 28, 2025 September 29, 2024

(in thousands) (in thousands)

5 unchanged sentences

See Note 10 entitled “Segment Information” of Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information.

During the second quarter of 2025, net sales in EAAA increased 3.4% versus the comparable period in 2024, primarily due to favorable currency fluctuations of approximately $4.6 million (3.5%) from the strengthening of the Euro against the U.S.

dollar, partially offset by lower volume.

On a market segment basis, the EAAA sales increase was primarily in the public buildings and transportation market segments.

During the first six months of 2025, net sales in EAAA increased 0.8% versus the comparable period in 2024, primarily due to favorable currency fluctuations of approximately $1.0 million (0.4%), higher sales volume and average sales prices.

On a market segment basis, the EAAA sales increase was primarily in the transportation, public buildings, and healthcare market segments, mostly offset by a decrease in the corporate office market segment.

AOI in EAAA decreased 44.2% during the second quarter of 2025 versus the comparable period in 2024, primarily due to lower gross profit margin driven by unfavorable fixed cost absorption and higher input costs.

Currency fluctuations had no material impact on EAAA AOI for the second quarter of 2025 compared to the same period last year.

As a percentage of net sales, AOI decreased to 5.2% during the second quarter of 2025 compared to 9.6% in the same period last year.

AOI in EAAA decreased 37.0% during the first six months of 2025 versus the comparable period in 2024, primarily due to lower gross profit margin as discussed above.

Currency fluctuations had no material impact on AOI for the first six months of 2025 compared to the same period in 2024.

As a percentage of net sales, AOI decreased to 5.0% during the first six months of 2025 compared to 8.0% in the same period last year.

During the third quarter of 2025, net sales in EAAA increased 8.8% versus the comparable period in 2024, primarily due to favorable currency fluctuations of approximately $6.0 million (4.5%) from the strengthening of the Euro against the U.S.

dollar, higher sales volume, and higher average sales prices.

On a market segment basis, the EAAA sales increase was primarily in the corporate office, transportation, and healthcare market segments.

During the first nine months of 2025, net sales in EAAA increased 3.6% versus the comparable period in 2024, primarily due to favorable currency fluctuations of approximately $7.0 million (1.8%), higher sales volume, and higher average sales prices.

On a market segment basis, the EAAA sales increase was primarily in the transportation, public buildings, and healthcare market segments, partially offset by a decrease in the corporate office market segment.

AOI in EAAA increased 21.0% during the third quarter of 2025 versus the comparable period in 2024, primarily due to higher gross profit margin primarily driven by higher average sales prices.

Currency fluctuations had a positive impact on EAAA AOI of approximately $1.2 million (5.6%) for the third quarter of 2025 compared to the same period last year.

As a percentage of net sales, AOI increased to 9.4% during the third quarter of 2025 compared to 8.4% in the same period last year.

AOI in EAAA decreased 16.2% during the first nine months of 2025 versus the comparable period in 2024, primarily due to lower gross profit margin driven by higher raw material input costs and unfavorable fixed cost absorption in our manufacturing facilities.

Currency fluctuations had a positive impact on AOI of approximately $1.5 million (2.4%) for the first nine months of 2025 compared to the same period in 2024.

As a percentage of net sales, AOI decreased to 6.6% during the first nine months of 2025 compared to 8.1% in the same period last year.

Financial Condition, Liquidity and Capital Resources

At June 29, 2025, the Company had $121.7 million in cash.

At September 28, 2025, the Company had $187.4 million in cash.

At that date, the Company had $5.5 million in term loan borrowings, $4.6 million in revolving loan borrowings, and $0.6 million in letters of credit outstanding under our Facility, and we had $300.0 million of Senior Notes outstanding.

As of June 29, 2025, we had additional borrowing capacity of $298.2 million under the Facility.

As of September 28, 2025, we had additional borrowing capacity of $294.8 million under the Facility.

We anticipate that our liquidity is sufficient to meet our obligations for the next 12 months, and we expect to generate sufficient cash to meet our long-term obligations.

1 unchanged sentence

The Company’s foreign subsidiaries and certain non-material domestic subsidiaries are considered non-guarantors.

Net sales for the non-guarantor subsidiaries were approximately $154 million and $283 million for the three-month and six-month periods ended June 29, 2025, respectively, and net sales for the non-guarantor subsidiaries were approximately $145 million and $278 million for the three-month and six-month periods ended June 30, 2024, respectively.

Total indebtedness of the non-guarantor subsidiaries was approximately $115 million and $102 million as of June 29, 2025 and December 29, 2024, respectively.

Net sales for the non-guarantor subsidiaries were approximately $159 million and $442 million for the three-month and nine-month periods ended September 28, 2025, respectively, and net sales for the non-guarantor subsidiaries were approximately $149 million and $427 million for the three-month and nine-month periods ended September 29, 2024, respectively.

Total indebtedness of the non-guarantor subsidiaries was approximately $13 million and $102 million as of September 28, 2025 and December 29, 2024, respectively.

During the three months ended September 28, 2025, certain outstanding debt owed by the non-guarantor subsidiaries was partially repaid and partially contributed by a guarantor subsidiary to the capital of a non-guarantor subsidiary, reducing total indebtedness of the non-guarantor subsidiaries by approximately $105 million.

Balance Sheet

Accounts receivable, net, were $194.3 million at June 29, 2025, compared to $171.1 million at December 29, 2024.

The increase of $23.1 million was primarily due to the impact of higher net sales as a result of increased customer demand in the second quarter of 2025.

Inventories, net, were $288.2 million at June 29, 2025, compared to $260.6 million at December 29, 2024.

Accounts receivable, net, were $187.1 million at September 28, 2025, compared to $171.1 million at December 29, 2024.

The increase of $16.0 million was primarily due to the impact of higher net sales as a result of increased customer demand in 2025.

Inventories, net, were $286.8 million at September 28, 2025, compared to $260.6 million at December 29, 2024.

The increase of $26.2 million was primarily due to finished goods inventory build attributable to higher expected customer demand in the remainder of 2025.

Analysis of Cash Flows

The following table presents a summary of cash flows for the six-month periods ended June 29, 2025 and June 30, 2024, respectively:

Six Months Ended

June 29, 2025 June 30, 2024

The following table presents a summary of cash flows for the nine-month periods ended September 28, 2025 and September 29, 2024, respectively:

Nine Months Ended

September 28, 2025 September 29, 2024

(in thousands)

7 unchanged sentences

Cash and cash equivalents at end of period $ 187,355 $ 115,601

Cash provided by operating activities was $41.9 million for the six months ended June 29, 2025, which represents an increase of $7.7 million from the prior year comparable period, primarily attributable to higher net income for the six months ended June 29, 2025, partially offset by a higher use of cash related to inventory build as discussed above.

Cash used in investing activities was $14.8 million for the six months ended June 29, 2025, which represents an increase of $3.3 million from the prior year comparable period, primarily attributable to a greater capital investment in manufacturing automation and robotics solutions during the first six months of 2025.

Cash used in financing activities was $13.7 million for the six months ended June 29, 2025, which represents a decrease of $23.2 million from the prior year comparable period.

The decrease was primarily attributable to lower outstanding borrowings under the credit facility resulting in lower repayments during the first six months of 2025 compared to the prior year period.

Additionally, the repurchase of common stock during the second quarter of 2025 contributed to the use of cash for the current period.

Cash provided by operating activities was $118.6 million for the nine months ended September 28, 2025, which represents an increase of $8.2 million from the prior year comparable period, primarily attributable to higher net income for the nine months ended September 28, 2025, partially offset by a higher use of cash related to inventory build as discussed above.

Cash used in investing activities was $25.5 million for the nine months ended September 28, 2025, which represents an increase of $8.8 million from the prior year comparable period, primarily attributable to a greater capital investment in manufacturing automation and robotics solutions during the first nine months of 2025.

Cash used in financing activities was $14.0 million for the nine months ended September 28, 2025, which represents a decrease of $75.6 million from the prior year comparable period.

The decrease was primarily attributable to lower outstanding borrowings under the credit facility resulting in lower repayments during the first nine months of 2025 compared to the prior year period.

Additionally, the repurchase of common stock during the first nine months of 2025 contributed to the use of cash for the current period.

Share Repurchases

In the May 2022, the Company adopted a share repurchase program in which the Company is authorized to repurchase up to $100 million of its outstanding shares of common stock.

In May 2022, the Company adopted a share repurchase program in which the Company is authorized to repurchase up to $100 million of its outstanding shares of common stock.

The program has no specific expiration date.

During the six months ended June 29, 2025, the Company repurchased 217,500 shares of common stock at a weighted average price of $20.44 per share pursuant to this program.

Based on strong second quarter 2025 results, we increased our outlook for the full fiscal year of 2025, while acknowledging a dynamic and uncertain global macroeconomic environment.

We anticipate net sales growth in the third quarter of fiscal year 2025 compared with the same period last year.

During the nine months ended September 28, 2025, the Company repurchased 250,000 shares of common stock at a weighted average price of $20.57 per share pursuant to this program.

Based on the strength of our third quarter and year to date 2025 results, we increased our outlook for the full fiscal year of 2025, while acknowledging a challenging and uncertain global macroeconomic environment.

We anticipate net sales growth in the fourth quarter of fiscal year 2025 compared with the same period last year.

We also expect to incur tariff costs during the remainder of 2025, and we anticipate offsetting these costs through pricing and productivity initiatives.

1 unchanged sentence

However, the Company’s cash flows from operations can be affected by numerous factors including raw material availability and cost, and demand for our products.

As of July 20, 2025, the consolidated backlog of unshipped orders was approximately $263.2 million.

As of October 19, 2025, the consolidated backlog of unshipped orders was approximately $244.4 million.

As disclosed in our Annual Report on Form 10-K for the fiscal year ended December 29, 2024, backlog was approximately $223.4 million as of February 2, 2025.

1 unchanged sentence

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 2. Management’s Discussion and Analysis